Head to Head Survey: Catalent (CTLT) versus Its Rivals

Catalent (NYSE: CTLT) is one of 104 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Catalent to related businesses based on the strength of its profitability, earnings, analyst recommendations, risk, dividends, institutional ownership and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Catalent and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Catalent 0 2 5 0 2.71
Catalent Competitors 871 3795 6770 181 2.54

Catalent currently has a consensus target price of $43.71, suggesting a potential upside of 15.40%. As a group, “Pharmaceuticals” companies have a potential upside of 25.79%. Given Catalent’s rivals higher possible upside, analysts plainly believe Catalent has less favorable growth aspects than its rivals.

Volatility and Risk

Catalent has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Catalent’s rivals have a beta of 34.62, meaning that their average share price is 3,362% more volatile than the S&P 500.

Profitability

This table compares Catalent and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Catalent 5.01% 23.97% 5.24%
Catalent Competitors -2,401.92% -68.94% -7.32%

Insider & Institutional Ownership

99.5% of Catalent shares are held by institutional investors. Comparatively, 44.8% of shares of all “Pharmaceuticals” companies are held by institutional investors. 1.7% of Catalent shares are held by insiders. Comparatively, 11.4% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Catalent and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Catalent $2.08 billion $109.80 million 43.54
Catalent Competitors $8.17 billion $1.09 billion 140.72

Catalent’s rivals have higher revenue and earnings than Catalent. Catalent is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Catalent rivals beat Catalent on 7 of the 13 factors compared.

Catalent Company Profile

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

What are top analysts saying about Catalent Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Catalent Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit